A reversible, selective inhibitor of MAO-B (IC50 = 0.1 μM); also blocks voltage-sensitive sodium channels, N- and L-type calcium channels, and glutamate and aspartate release from synaptic terminals; has benefits in the management of Parkinson's disease when combined with dopamine agonists or L-DOPA